Clinical Development of Therapies for Charcot–Marie–Tooth Disease: Recommendations for Trial Design, Endpoints, and Regulatory Pathways Authors: Charles K. Abrams, Sue Bruhn, Joshua Burns, Rebekah Fleming, Katherine Forsey, Vera Fridman, David N. Herrmann, Brian Lin, Susan McCune, Allison Moore, Susan Ruediger, Michael Shy, Shannon Strom, Shannon Strom, Shannon Strom, Peggy Allred, Dottie M. Caplan, Samuel Collins, David Goldstein, Christina Greeley, Benit S. Maru, Thomas Holm Pedersen, Terry Pirovolakis, Rachel Salzman, Iris Schultz Published: 2026 ABSTRACT ABSTRACTCharcot–Marie–Tooth disease (CMT) encompasses a heterogeneous group of inherited peripheral neuropathies. Despite being the most common genetic neurological condition, individual CMT subtypes are rare, presenting unique challenges for therapeutic development. The Together Patients Industry Clinicians versus CMT (ToPIC: CMT) Advocacy Group was formed with a diverse group of patient advocacy groups, clinician‐scientists who treat patients with CMT, and pharmaceutical industry representatives to develop a common guidance on development of new treatments for CMT with clear expectations for meaningful patient outcomes and objective assessments of improvement. The ToPIC: CMT Group developed recommendations for clinical development of drugs and biological products for treating CMT, addressing trial design considerations for this rare progressive disease. Key challenges in CMT include small patient populations, variable disease progression, and the need for sensitive outcome measures. Recommendations emphasize flexible trial designs including adaptive designs, external controls, and single‐participant designs when scientifically justified. Where possible, broad inclusion criteria based on clinical phenotype rather than genetic subtype alone are recommended. Disease‐specific, validated outcome measures should assess function across ages and disease stages. Biomarkers reflecting peripheral nervous system health may serve as surrogate endpoints to support accelerated approval pathways. Patient and care partner perspectives are essential throughout development, particularly regarding treatment goals, risk tolerance, and meaningful endpoints. Successful therapeutic development for CMT and related neuropathies requires innovative approaches that balance rigorous scientific standards with the realities of rare disease research. Regulatory flexibility, informed by patient input and natural history data, can facilitate efficient development while maintaining assurance of safety and effectiveness. Introduction Charcot–Marie‐Tooth disease (CMT) represents a collection of inherited peripheral neuropathies that collectively constitute the most common genetic neurological condition worldwide, affecting approximately 1 in 2500 people [1, 2]. Individual subtypes of CMT are rare disorders that are often progressive, serious, and functionally debilitating. The disease affects individuals of both sexes and all backgrounds, and most patients experience onset in the first or second decade of life. CMT is commonly subdivided into two main forms: demyelinating (CMT Type 1 [CMT1] and CMT Type 4), in which demyelination or dysmyelination is the primary pathology, and axonal (CMT Type 2 [CMT2] and other rare subtypes), characterized by primary axonal degeneration [2]. Common clinical manifestations include significant, progressive muscle weakness and sensory loss, typically beginning distally in the lower extremities and advancing proximally and to the upper extremities. Many individuals develop serious difficulties with walking due to foot and ankle weakness, sensory loss, and imbalance, as well as problems with hand dexterity and fine motor tasks that eventually limit independence and quality of life. Progressive muscle weakness and painful foot deformities commonly result in a need for orthoses, bracing, or orthopedic surgery. As the disease progresses, affected individuals experience considerable emotional and social burden related to their symptoms [3]. Many patients ultimately experience significant disability, including reduced ability to work, wheelchair dependence, and diminished quality of life [4]. To date, more than 140 genetic causes of CMT have been identified. The most common mutation is duplication of PMP22, which causes CMT1A and accounts for ~50% of patients. The next most frequent forms are CMTX1 (pathogenic variants in GJB1), CMT2A (pathogenic variants in MFN2), and CMT1B/CMT2J (pathogenic variants in MPZ). Together, these genetic subtypes account for ~85% of all CMTs and are estimated to each affect between 5400 and 55 000 patients in the United States [5]. Nearly all other CMT2 types constitute less than 1% of cases, with likely fewer than 1500 US patients for each genetic subtype. Additionally, ~25%–40% of patients do not have a confirmed genetic diagnosis or have a variant of unknown significance, and many patients are diagnosed phenotypically and lack an underlying genetic diagnosis [2]. Natural history studies have demonstrated a shared clinical phenotype across genetic subtypes, with commonalities in disease progression [6, 7, 8, 9, 10, 11]. Patients generally experience progressive length‐dependent sensorineural loss, distal extremity weakness, and loss of gross and fine motor skills limiting gait, balance, and function. While differences exist even within families in age of onset or rate of progression [12], natural history data suggest that therapeutic approaches addressing common clinical symptomology could be applied across genetic phenotypes. The realities of limited patient numbers, particularly for specific genetic subtypes, and variable or slow disease progression for the most common subtypes of CMT necessitate flexible approaches to clinical trial design. These include use of phase‐appropriate, validated, disease‐specific, and highly sensitive outcome measures; identification of surrogate biomarkers; and thoughtful consideration of appropriate study populations and control groups. While the focus of this manuscript is on the United States Food and Drug Administration (FDA), global regulatory health authorities including the FDA, the European Medicines Agency (Europe), the Pharmaceuticals and Medical Devices Agency (Japan), the National Medical Products Administration (China), and the Medicines and Healthcare products Regulatory Agency (United Kingdom) share a common regulatory philosophy toward rare disease drug development, while maintaining operationally jurisdiction‐specific requirements, incentives, and evidentiary expectations and, as such, the recommendations of this manuscript may be applied globally. The Together Patients Industry Clinicians versus CMT (ToPIC:CMT) Advocacy Group was formed with CMT patient advocacy groups (PAGs), clinicians who treat patients with CMT, and pharmaceutical industry representatives to develop a common guidance on development of new treatments for CMT with clear expectations for meaningful patient outcomes and objective assessments of improvement. The group focused on the following areas: (1) natural history, diagnosis, trial design, and outcome measures; (2) patient experience and benefit/risk; (3) biomarkers and surrogate endpoints; (4) safety, (5) gene therapy; and (6) pediatric development. The recommendations in this guidance have been discussed within the CMT scientific community and represent a forward‐looking, patient‐focused, data‐centered approach for development of new therapies for this rare disorder. General Product Development Considerations Engagement With Patients and Stakeholders Early communication between clinical trial sponsors and those affected by CMT is essential during drug development. Given that CMT is characterized by progressive and ultimately serious disability as well as significant emotional and social burden, either a lack of progression or slowing of disease progression may represent a desirable therapeutic outcome for the patient community. Therapeutic context, including disease severity and morbidity and the level of unmet need, may justify greater risks and uncertainties about risks [13]. Understanding how affected individuals view treatment goals and tolerance for risk and uncertainty, as well as the relationship between treatment goals and risk tolerance based on specific disease experience, is critical. Tolerance for risk may differ among patients based on CMT subtype, disease severity, or disease presentation in older family members. As therapeutic development proceeds and potential benefits and risks become more clearly understood, sponsors should continue eliciting input from patients, care partners, and PAGs. Patients' treatment goals may differ depending on specific circumstances such as age, rate of progression, and disease stage. Patients most severely affected, their care partners, and PAGs can provide insight into the most appropriate outcomes to designate as primary endpoints, optimal assessment methods, and meaningfulness of treatment effects within the disease context. Well‐designed patient‐reported outcome (PRO) tools can be particularly powerful in measuring treatment effects in CMT. Patients, care partners, and PAGs can also provide insight regarding preferences and tolerance for different routes and frequencies of therapeutic administration. Study Population Considerations In general, sponsors should base eligibility for enrollment in effectiveness trials on current consensus diagnostic criteria, focusing on history, physical examination, and objective functional tests. With the exception of therapies targeting specific genetic mutations or variants, participants with a clinical presentation consistent with CMT should not require a known genotype for trial eligibility. When a specific genetic mutation leads to altered expression of a biomarker, this biomarker may be considered for determining enrollment eligibility. Understanding safety and efficacy across phenotypes, genetic subtypes, and disease stages is essential. Although sponsors may use prognostic enrichment to increase likelihood of demonstrating drug effect (e.g., enrolling patients with mild or moderate disease severity) or predictive enrichment to direct therapy to patients with particular disease characteristics (e.g., specific phenotype or genetic subtype), patients should not be excluded based on characteristics such as age, CMT type (demyelinating vs. axonal), or disease stage unless scientifically justified. Clinical manifestations are often highly similar across genetic subtypes, and study populations should reflect commonalities based on clinical phenotypes rather than assuming underlying genetic causes represent separate populations. For example, clinical trials of treatments addressing or limiting axonal loss should consider potential impact in patients with primarily demyelinating CMT1, in which axonal damage invariably occurs, in addition to patients with primarily axonal CMT2. Enrollment of populations representative of clinical phenotypes may allow extrapolation of trial results to genotypes beyond those studied. Therefore, when treatment outcomes or mechanisms address clinical symptoms broadly, use should be considered in appropriate clinical populations not limited to the genetic phenotypes studied in pivotal trials. However, for targeted therapies against a mutation‐specific molecular pathway, consideration should be given to the risk of diluting a treatment effect if broad inclusion criteria could allow subjects into the trial that do not have the genetic mutation unless conservation of the pathway across subtypes has been confirmed. Broader inclusion criteria can allow more rapid trial enrollment and potentially accelerate drug development, particularly for rare genotypes. In pivotal trials, an acceptable approach could include enrollment of a broad population with primary analysis conducted in a more homogeneous subset defined by clinical characteristics and/or biomarkers, with analyses of the broader population being secondary and supportive. Strong rationale exists for treatment at an early age, as drugs preserving myelin or preventing axonal damage may have greatest benefit before muscle strength has deteriorated. As CMT affects individuals across the lifespan, assessing safety and efficacy at later disease phases is also necessary, including stages when axonal damage and muscle weakness are advanced. Pediatric Development Many patients experience CMT symptom onset during childhood [14]. Historically, pediatric clinical investigations only began after adult efficacy data and safety were available. While understanding safety issues in adults is important, enrolling the age group with the best chance of responding to treatment is critical. Because children with aggressive forms of CMT may already depend on wheelchairs, this approach includes initiating therapy at the youngest age that is scientifically and ethically justified, providing the greatest prospect for preservation or improvement of function. A recent advancement in the rare disease field, and one that is recommended for CMT patients, is to focus first on the population with the optimal prospect of direct therapeutic response even in early‐phase trials, because early intervention could prevent disease progression and significant disability and preserve quality of life. Another staged approach is to conduct studies first in adolescents (12–17 years old) before examining younger children. To address the practical and ethical challenges, special considerations apply to conducting studies in children and the types and contexts of acceptable risks [15]. Within ethical considerations, in studies where risk to children exceeds minimal levels, drug development may proceed under the FDA regulatory framework if risk is justified by anticipated benefit and the relation of anticipated benefit to risk is at least as favorable as available alternative approaches [16]. However, patients and care partners can make appropriate decisions about participation only if they are provided clear information about potential risks and benefits. Beyond informed consent, and child assent when applicable, communicating emerging safety information to study participants and care partners is critical to allow reassessment of continued participation. Efficacy trial design. Effiacy Trial Design Study Design Approaches Randomized placebo‐controlled trials generally represent the most efficient approach for demonstrating drug efficacy in CMT. However, because CMT is an irreversibly progressive disease with significant unmet need that can lead to severe disability, minimizing unnecessary placebo exposure benefits participants. In some circumstances, trials using single‐participant design (each participant's baseline serves as their own control) or external controls (e.g., historically controlled trials or concurrent natural history studies) may constitute adequate and well‐controlled studies that may contribute to evidence of efficacy to support approval for rare diseases. The collection of prospective natural history data is important to further understand the variability among patients, the rate of disease progression, and the adequate statistical powering of trials for the assessment of therapeutic interventions. When the natural history of a CMT subtype is well‐characterized and the heterogeneity of disease course is sufficiently understood, the use of historically controlled trials in that population may be appropriate. In some cases, to increase the data available, historical controls may be able to extrapolate across genetic subtypes with similar clinical courses or include multiple genetic subtypes based on phenotype. Sponsors are encouraged to discuss with regulators whether innovative trial designs can be justified in order to facilitate efficient product development while limiting the use of placebo cohorts. However, historically controlled trials lack important design features that reduce bias, such as randomization and masking of treatment assignment, and generally are persuasive to regulatory authorities only when drug effects are large on objective endpoints that are less susceptible to bias [17, 18, 19]. To support reliance on single‐participant design or externally controlled studies, sponsors should present detailed evidence that study design and conduct are adequately controlled for bias. Potential bias sources, such as differences in encouragement during performance or function tests, should be eliminated or minimized. For historical controls, it would be critical to establish that the control group was prospectively well matched to the treatment group across important baseline and prognostic variables, including age, baseline value of the primary efficacy measure and other measures of disease stage or level of disability, type and intensity of supportive care, and dose and duration of concomitant pharmacotherapies, among others. The disease course in an external patient cohort can be sensitive to the date of inception and the age of patients at inception. Thus, selection of these parameters with data in hand can introduce bias. Because of the inherent limitations of externally controlled trials, only large treatment effects are likely to be convincing. For CMT subtypes with highly variable or limited natural history, randomized placebo‐controlled trials may be preferred for obtaining persuasive evidence of clinical effectiveness. However, single‐arm trials with baseline characterization of individual participants serving as their own control may be considered when CMT subtype prevalence or rapid disease progression justifies an alternative to placebo‐controlled design. To facilitate rapid clinical development, sponsors are encouraged to design Phase 1 studies to include proof‐of‐concept evaluation of efficacy in participants with CMT to gather preliminary evidence of potential effectiveness. To maximize use of the small number of CMT patients available for clinical trial participation, sponsors should consider combination Phase 1/2 and Phase 2/3 designs. Trials should be of reasonable duration to minimize participant burden, especially for those randomized to placebo. Enrolling participants in multiple subsequent trials (Phase 1, 2, and 3) should be considered when the study population is very small. Given the geographic dispersion of CMT patients and the mobility limitations associated with progressive neuropathy, remote assessments, telemedicine visits, wearable digital health technologies, and direct‐to‐patient drug shipment may reduce participant burden and improve recruitment and retention to aid sponsors in rapid clinical development. Sponsors should consider designing trials to include prespecified plans for a long‐term, open‐label extension. This extension should allow for additional prespecified effectiveness assessments. The appointment of an independent monitoring board should be considered when an adaptive design is planned or when the possibility of unblinding is included in the trial design. The use of real‐world evidence (RWE) data to support approval of new products is becoming more routine in clinical development, and RWE data may offer another approach for very rare CMT subtypes. FDA has recently introduced the plausible mechanism framework to develop new individualized treatments for pathogenic variants using adequate and well‐controlled trials with small sample sizes and confirmatory evidence from other nonclinical or clinical sources [20]. Efficacy Endpoints No defined set of FDA required or recommended clinical outcome measures exists for CMT studies. Although existing CMT‐specific outcome measures developed for clinical trials and/or clinical care may be appropriate, novel outcome measures capable of measuring clinically meaningful patient effects should be considered. Sponsors are encouraged to propose and, if necessary, develop endpoints that can validly and reliably assess patients with a wide spectrum of symptoms and disease stages. Early engagement with regulators during efficacy endpoint selection and/or development is encouraged. When feasible, clinical trial designs should include assessments of multiple efficacy endpoints to characterize the breadth of effects on CMT‐related pathologies, even if only a single measure is designated as the primary endpoint. Efficacy endpoints that can measure change of function over a wide range of types and severity of deficits may offer several advantages in the development of drugs for CMT. Such endpoints may increase the number of patients eligible for enrollment and may decrease possible loss of information from floor effects, which occur when patients are no longer able to perform a function, and ceiling effects, which occur when patients remain capable of performing a function at maximal ability and a measurable change (e.g., improvement) cannot be detected throughout the study. For these reasons, sponsors are encouraged to select endpoints that can assess function across different stages of the disease (e.g., by combining measures of walking and upper body function). Endpoints should encompass the ability to evaluate improvement, stabilization, and decline from baseline, to capture the spectrum of possible beneficial drug effects. Efficacy endpoints based on function can be measured in various ways, including performance‐based clinical outcome assessments (COAs) demonstrating patient ability to perform specific activities or activity sets (e.g., ability to perform the activity; time required) or as time to event for decline or loss of ability. For young children, whose abilities are still developing, measuring the time to achieve developmental milestones (i.e., a positive time‐to‐event endpoint) may be appropriate. Measuring functional outcomes in patients who rely on mobility devices including ankle‐foot orthoses (AFOs) is complex and may limit both the eligible patient population and the ability to detect change in some measures. In slowly progressive disease, detecting clinically meaningful change within a reasonable timeframe presents significant challenges, particularly when disease manifestations involve subtle changes across multiple functional domains that, in aggregate, substantially impact patient function. Several measures have been developed and assessed for CMT patients in natural history studies. These COAs are largely based on multifactorial functional assessments designed to capture the complicated range of symptomology faced by CMT patients. Performance‐based outcome assessments that measure change in functional ability in adults have been developed, such as the CMT‐FOM, and extended to pediatric patients and infants, such as the CMTPedS and CMTInfS [21, 22, 23, 24, 25]. COA domains include measurements of strength, upper limb function, lower limb function, balance, nerve conduction amplitudes, and mobility. Sponsors should work closely with regulators to assess whether integrated outcome measures, or components that address specific clinical aspects of treatment, are best to assess the effects of treatments on clinical outcomes. Patient‐reported outcomes (PROs), including those measuring activities of daily living, can be designed to assess patient abilities and experiences across a spectrum of disease stages and severities. PROs can be useful to assess the clinical meaningfulness of an objective finding of relatively small magnitude and to contribute to assessments of benefit and risk. PRO instruments for CMT, such as the CMT Health Index (CMT‐HI) [26, 27], generally should include items that assess the most important aspects of the outcome of interest (e.g., specific aspects that contribute to health‐related quality of life, such as physical functioning). In cases where a participant is unable to report for himself or herself (e.g., a young child), the sponsor should base observer‐reported outcomes on what a care partner or other observer directly sees during a participant's daily activities. Where disease‐specific, validated clinical assessments and PROs are available, as is the case with CMT, those assessments and PROs should be strongly considered for use as endpoints in a clinical trial. Study Procedures and Duration Drugs that will be chronically administered to patients with CMT should be shown to be effective for a reasonable period of time (i.e., at least 3 months). For drugs expected to slow functional decline, study duration should consider the anticipated rate of disease progression in addition to predicted drug efficacy. Sponsors should base the duration of studies on scientifically justifiable sample size calculations that include, when appropriate, the predicted rate of functional decline in the control group, the anticipated effect size, the variability around these estimates, and the desired statistical power. Statistical Considerations Statistical approaches for CMT should generally be similar to those used in other rare, progressive neurological diseases. Sponsors can use designs that increase the efficiency of studies (e.g., adaptive designs) [28]. Adaptive study designs may be desirable in certain circumstances, as they permit modifications to aspects of the clinical trial based on data that was not available when the trial initiated. Adaptive features may include, but are not limited to, group sequential designs, sample size re‐estimations, participant allocation, or endpoint selection. Bayesian adaptive features/designs may be particularly useful for studies with small populations. For efficacy assessment based on a continuous measurement of functional capacity, sponsors generally should perform statistical analyses on the change from baseline for each treatment group, with the treatment effect assessed by comparing the mean changes between the treatment and control groups at one or more specific times. The mean changes would normally be adjusted for the baseline measurement to improve statistical power for detecting a treatment effect. Overall, a study should be adequately powered to be able to detect a treatment effect in the study population taking into account the estimated effect size. Because of the limited number of patients with CMT, however, it may not be realistic or feasible to adequately power the study to attain statistically significant results for each distinct subpopulation of interest. If the sponsor has obtained statistically significant results demonstrating efficacy in the overall target population, favorable trends in the efficacy results may support the inclusion of a description of subpopulations within the clinical trials section of product labeling. As appropriate, sponsors may consider obtaining a baseline assessment on more than one occasion to assess intra‐subject variability. For studies that require a specific degree of physical disability for enrollment, the screening assessment used to qualify participants for study entry should not be used as the baseline assessment. A sponsor should obtain a separate baseline assessment after the screening assessment to limit regression to the mean. For CMT, sponsors can also consider a variation of this approach that assesses the change from baseline in the slopes (or rates of change). Whereas the typical change from baseline assessment takes only 2 measurements into consideration (pretreatment and posttreatment at a particular time point), assessment of slope change takes multiple measurements into consideration for each participant, thereby possibly improving statistical power to show a treatment difference. The likelihood that randomization will be fully successful in producing comparable study arms can be increased through stratified randomization based on one or more prognostic factors. With small to moderate sample sizes, however, sponsors should limit such covariates to a few that are carefully chosen. Sponsors should consider prospectively including plans for interim effectiveness analyses to allow early detection of benefit in clinical trials. Biomarkers and Accelerated Approval In CMT, biomarkers that reliably reflect the health of the peripheral nervous system at a biochemical, cellular, or tissue level may be useful across the drug development process, including use as prognostic, predictive, or pharmacodynamic markers, or, if supported by sufficient scientific evidence and acceptable analytical methods, as surrogate endpoints to support accelerated approval. A single biomarker measure can serve different functions in different circumstances; for example, baseline neurofilament light chain (NfL; as a marker of axonal degeneration), or peripheral myelin protein 22 (PMP22; elevated in CMT1A) expression could be a marker of a patient's prognosis whereas a decrease in NfL or PMP22 could reflect biological activity of a drug and guide key aspects of drug development, such as dose selection and route of administration. Even if it cannot be concluded that a given biomarker can serve as a surrogate endpoint, positive findings based on a biomarker may help support the mechanism of action of a drug, help identify the appropriate patient population to study or treat, or support the validity of findings on other endpoints. To support continued progress in overall drug development for CMT, trials with clinically meaningful endpoints should include a selection of relevant biomarkers to help establish the relationship between such biomarkers and clinical endpoints. The potential for a biomarker to predict clinical benefit in CMT could relate to the magnitude of change of the biomarker and tissue in which the biomarker is measured. The meaning of a change in a biomarker might also depend on the age or disease stage of a patient or on other patient factors, such as inflammation. When biomarkers are assessed, analytical validity should be demonstrated to the extent possible, and there should be adequate assessment of the performance characteristics of the biomarker assay, including quality‐control measures and documentation of results. When a change in a biomarker is considered reasonably likely to predict clinical benefit, that biomarker may be an acceptable surrogate endpoint for accelerated approval [29, 30, 31, 32]. This may include biomarker evidence that the treatment has altered a critical disease pathway at the cellular level or if the mechanism of action of the therapy directly affects the etiology of the disease or other endpoints that are meaningful to patients. For certain gene therapies, a change in functional genetic mechanism of action (e.g., transgene expression) alone could qualify as a surrogate marker for approval; however, in other instances, complementary biomarker data may be needed to support accelerated approval. Additional radiologic and physiologic biomarkers for consideration include: Quantitative measurement of muscle fat fraction using magnetic resonance imaging. Advantages of imaging include its noninvasiveness, its ability to assess large samples of muscle, the fact that it can be performed repeatedly at multiple time points, and its ability to assess multiple regions of the body, including foot, calf, and thigh, which are of particular relevance to CMT and can be variably affected in different stages of disease [33, 34, 35].Digital biomarkers collected remotely using emerging wearable digital health technologies, as these measures may better reflect daily life and reduce participant burden of study visits [36]. Quantitative measurement of muscle fat fraction using magnetic resonance imaging. Advantages of imaging include its noninvasiveness, its ability to assess large samples of muscle, the fact that it can be performed repeatedly at multiple time points, and its ability to assess multiple regions of the body, including foot, calf, and thigh, which are of particular relevance to CMT and can be variably affected in different stages of disease [33, 34, 35]. Quantitative measurement of muscle fat fraction using magnetic resonance imaging. Advantages of imaging include its noninvasiveness, its ability to assess large samples of muscle, the fact that it can be performed repeatedly at multiple time points, and its ability to assess multiple regions of the body, including foot, calf, and thigh, which are of particular relevance to CMT and can be variably affected in different stages of disease [33, 34, 35]. Digital biomarkers collected remotely using emerging wearable digital health technologies, as these measures may better reflect daily life and reduce participant burden of study visits [36]. Digital biomarkers collected remotely using emerging wearable digital health technologies, as these measures may better reflect daily life and reduce participant burden of study visits [36]. Sponsors considering development programs intended to support accelerated approval should discuss selection of outcome measures and surrogate biomarkers with the appropriate regulators early in drug development. Safety Considerations Phase 1 studies can be conducted in healthy volunteers or in participants with CMT, depending on administration method, safety profile, and potential for detecting pharmacodynamic responses in healthy volunteers relative to CMT participants. For cellular and gene therapy products, sponsors should carefully consider the appropriate Phase 1 study population of CMT participants. To support marketing approval, drug safety should be supported by an adequate number and duration of patient exposures to characterize drug risks [37]. It is important to consider CMT's serious nature, the prevalence of the specific patient population under investigation [38, 39], and potential for treatment benefit when determining minimum number and duration of patient exposures needed [40]. If dose and treatment duration, disease phenotype, and clinical severity are similar across different CMT subtypes [1], sponsors may leverage safety data from a product developed for one CMT subtype to support safety for other subtypes [41]. During development, sponsors should collect safety data, including data from open‐label studies or expanded access programs, from participants across the spectrum of disease stages and severities. In general, safety data from a reasonable number of patients exposed to the drug for at least 1 year is appropriate to support approval of drugs intended for chronic use in treating CMT [42]. The size of the recommended pediatric safety database of a drug product depends on several considerations in addition to those noted above, including the incidence of the disease, adverse event profile of the drug product or drug class, and expected use of the drug product in the pediatric population. Sponsors should discuss the size of the pediatric safety database with regulators as the clinical development of the drug product proceeds. The administration of cellular and gene therapy products may raise specific considerations regarding patient exposures; thus, we recommend that sponsors of such products discuss safety considerations with regulators. Sponsors should be aware that for products using a platform that has received platform technology designation, manufacturing and safety data from previously approved products may be leveraged to support review of new products based on the same platform [27]. Gene Therapy Considerations Prior FDA guidance remains applicable for many CMT gene therapy product aspects, including guidance for industry on human gene therapy for rare diseases (January 2020), chemistry, manufacturing, and control information for human gene therapy investigational new drug applications (January 2020), human gene therapy for neurodegenerative diseases (October 2022), manufacturing changes and comparability for human cellular and gene therapy products (July 2023), and platform technology designation program for drug development (May 2024). Despite limited statistical power, first‐in‐human trials of gene therapy products should be well‐controlled as results may provide evidence of effectiveness and guide further development. Safety considerations for CMT gene therapy products should align with previous regulatory guidance [43]. Sponsors should be aware of additional safety challenges, including adverse immune responses associated with gene therapy products, an important safety risk that must be monitored in participants with CMT after gene therapy administration. Preclinical studies in animal models do not fully capture all adverse events that occur in the clinic due to differences in immune systems among species [44]. Immune responses to gene therapy products require careful review of participant eligibility criteria, including considerations for pre‐existing antibodies, genetic background, and health complications. Sponsors should be aware that some adverse events may not appear within the timeframe of the clinical trials, and gene therapies require a well‐established long‐term follow‐up plan. The length of follow‐up necessary depends on many aspects of the gene therapy product, including safety, durability, transgene activity, and vector presence, and should be evaluated on a case‐by‐case basis. Sponsors should refer to FDA guidance for industry Long Term Follow‐Up After Administration of Human Gene Therapy Products (January 2020) for developing long‐term follow‐up protocols and discuss considerations with regulators. Sponsors should work with patients, care partners, and PAGs to ensure that the patient perspective is incorporated into informed consent materials for gene therapy trials, and the benefits and risks specific to these trials are clearly communicated. Benefit–Risk Considerations CMT is a serious, debilitating, and inexorably progressive group of inherited neuropathies with significant unmet need, and some subtypes cause rapid functional decline during childhood. When making regulatory decisions regarding drugs for CMT, it is important to consider patient and care partner tolerance for risk and the serious nature of the disease when assessing the benefit to risk considerations. For example, patients may be willing to tolerate increased risk of adverse events if a drug may impact an important unmet need, such as delaying the loss of important abilities like ambulation. The risk impact may be affected by disease stage and severity so the generalizability of the drug's benefits to all intended populations likely to be prescribed the drug is an important factor in benefit–risk calculations. 1 Regulatory flexibility should be exercised for treatments for serious rare diseases like CMT to demonstrate substantial evidence of effectiveness, and the United States FDA has issued guidance on the plausible mechanism framework for development of therapies for conditions with known genetic causes, like CMT [20]. Patient preference information can guide development of appropriate PROs to capture the important treatment attributes for patients and inform the risk‐to‐benefit assessment. Product Labeling Considerations Sponsors are encouraged to enroll patients across disease stages, phenotypes, and genetic subtypes. Data from even a relatively small number of patients across different CMT types may help to support an indication that includes broader groups of patients. In general, marketing approval should be considered for the broadest patient population possible based on the evidence package unless issues exist that provide arguments against such an approach (e.g., an unacceptable safety risk, an expected lack of effectiveness in certain subpopulations). Additional labeling considerations include the following: Therapies targeting the health of the myelin sheath should be considered for all types of dysmyelinating/demyelinating CMT, regardless of the genetic variant.Therapies targeting axonal degeneration should be considered for all CMT types, regardless of genetic variant.Therapies that address a particular clinical aspect of CMT, such as upper limb function, should be considered for all types of CMT that share the clinical aspect, regardless of genetic variant.If CMT subtypes are not studied in the clinical trial, but the mechanism of action is the same as the groups that were studied and extrapolation to this population is scientifically justified, the label should be inclusive of all those affected subtypes.Where safe, genetic therapies that can target all variants of the implicated gene, regardless of variant location, are applicable to all variants in that gene.Delivery vehicles that demonstrate effective targeting of the cell of interest should be relevant to all CMT subtypes that are generated in the cell of interest (e.g., targeting the Schwann cells is relevant to all demyelinating/dysmyelinating forms of CMT). Therapies targeting the health of the myelin sheath should be considered for all types of dysmyelinating/demyelinating CMT, regardless of the genetic variant. Therapies targeting the health of the myelin sheath should be considered for all types of dysmyelinating/demyelinating CMT, regardless of the genetic variant. Therapies targeting axonal degeneration should be considered for all CMT types, regardless of genetic variant. Therapies targeting axonal degeneration should be considered for all CMT types, regardless of genetic variant. Therapies that address a particular clinical aspect of CMT, such as upper limb function, should be considered for all types of CMT that share the clinical aspect, regardless of genetic variant. Therapies that address a particular clinical aspect of CMT, such as upper limb function, should be considered for all types of CMT that share the clinical aspect, regardless of genetic variant. If CMT subtypes are not studied in the clinical trial, but the mechanism of action is the same as the groups that were studied and extrapolation to this population is scientifically justified, the label should be inclusive of all those affected subtypes. If CMT subtypes are not studied in the clinical trial, but the mechanism of action is the same as the groups that were studied and extrapolation to this population is scientifically justified, the label should be inclusive of all those affected subtypes. Where safe, genetic therapies that can target all variants of the implicated gene, regardless of variant location, are applicable to all variants in that gene. Where safe, genetic therapies that can target all variants of the implicated gene, regardless of variant location, are applicable to all variants in that gene. Delivery vehicles that demonstrate effective targeting of the cell of interest should be relevant to all CMT subtypes that are generated in the cell of interest (e.g., targeting the Schwann cells is relevant to all demyelinating/dysmyelinating forms of CMT). Delivery vehicles that demonstrate effective targeting of the cell of interest should be relevant to all CMT subtypes that are generated in the cell of interest (e.g., targeting the Schwann cells is relevant to all demyelinating/dysmyelinating forms of CMT). Conclusions CMT presents unique challenges for therapeutic development due to its genetic heterogeneity, small patient populations for individual subtypes, and variable or slow progression in common forms. However, shared clinical phenotypes across genetic subtypes and increasing understanding of disease natural history provide opportunities for innovative approaches to therapeutic development. Success requires flexibility in trial design, including consideration of adaptive designs and surrogate biomarkers, while maintaining rigorous scientific standards. Patient engagement throughout the development process is essential for identifying meaningful endpoints and understanding risk–benefit tradeoffs that reflect patient priorities. Early enrollment of appropriate age groups, including pediatric patients when scientifically justified, may maximize the ability to detect treatment effect and therapeutic benefit by preventing irreversible disability. The use of disease‐specific, validated outcome measures that assess function across a spectrum of disease manifestations will be critical for demonstrating clinically meaningful treatment effects. Regulatory pathways including accelerated approval based on biomarkers may facilitate timely access to therapies for this serious condition with significant unmet need. Broad inclusion criteria and flexible approaches to demonstrating safety and efficacy across phenotypes can maximize the impact of limited clinical trial data while ensuring appropriate evidence of benefit for patients. Funding Open access to this publication is made possible by the CMT Research Foundation.